Cancer Family
Skin Neoplasm
CI-CAN-00000051Explore in graph →
Non-malignant346 active trials14 approved drugs74 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000051Explore in graph →
Clinical trials
1,424 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05781386 | A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors | unknown | Phase 1 | 255 | Jiangsu Simcere Biologics Co., LtdINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06037239 | Phase I/II Study of Linperlisib Plus Chidamide for R/R Cutaneous T-cell Lymphoma: a Prospective, Single-center Study | unknown | Phase 1 / Phase 2 | 53 | Peking Union Medical College HospitalOTHER | 1 | Sep 14, 2023 | clinicaltrials |
| NCT03982212 | A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible Tumors | unknown | Phase 1 | 10 | University of Kansas Medical CenterOTHER | 1 | May 19, 2023 | clinicaltrials |
| NCT05539157 | Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors | unknown | Phase 1 | 1 | Immorna Biotherapeutics, Inc.INDUSTRY | 1 | Apr 4, 2023 | clinicaltrials |
| NCT03775525 | Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer(GEN602) | unknown | Phase 1 | 127 | Genzada Pharmaceuticals USA, Inc.INDUSTRY | 1 | Dec 23, 2022 | clinicaltrials |
| NCT05602792 | A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 233 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Nov 2, 2022 | clinicaltrials |
| NCT04118868 | Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma. | unknown | Phase 1 | 10 | Sorrento Therapeutics, Inc.INDUSTRY | 1 | Oct 12, 2022 | clinicaltrials |
| NCT05569057 | A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma | unknown | Phase 1 | 100 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 7, 2022 | clinicaltrials |
| NCT02437279 | Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients(OpACIN) | unknown | Phase 1 | 20 | The Netherlands Cancer InstituteOTHER | 1 | Apr 15, 2022 | clinicaltrials |
| NCT03291002 | Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC | unknown | Phase 1 | 98 | CureVacINDUSTRY | 5 | Nov 4, 2021 | clinicaltrials |
| NCT04138342 | Topical Fluorescent Nanoparticles Conjugated Somatostatin Analog for Suppression and Bioimaging Breast Cancer | unknown | Phase 1 | 30 | Al-Azhar UniversityOTHER | 2 | Oct 24, 2019 | clinicaltrials |
| NCT02654821 | Study With T-cel Receptor Gene Therapy in Metastatic Melanoma(TCR) | unknown | Phase 1 / Phase 2 | 12 | The Netherlands Cancer InstituteOTHER | 1 | Nov 2, 2018 | clinicaltrials |
| NCT02154451 | Transient Infrared Imaging for Early Detection of Skin Cancer | unknown | Phase 1 / Phase 2 | 400 | Skinfrared LLCOTHER | 1 | Jun 3, 2014 | clinicaltrials |
| NCT00423397 | Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer | unknown | Phase 1 / Phase 2 | 16 | University of California, San DiegoOTHER | 1 | Dec 19, 2013 | clinicaltrials |
| NCT01043016 | Safety Study of Photodynamic Therapy Using Photocyanine Injection in Treating Patients With Malignant Tumors | unknown | Phase 1 | 18 | Fujian Longhua Pharmaceutical Co. LtdOTHER | 1 | Jan 6, 2010 | clinicaltrials |
| NCT00779896 | Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study | unknown | Phase 1 / Phase 2 | 15 | McGill UniversityOTHER | 1 | Oct 24, 2008 | clinicaltrials |
Data updated 22 days agoSource updated Sep 21, 2023source: clinicaltrials